132 related articles for article (PubMed ID: 38497887)
21. Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
Stearns V; Brufsky AM; Verma S; Cotter MJ; Lu DR; Dequen F; Joy AA
Clin Breast Cancer; 2018 Dec; 18(6):e1239-e1245. PubMed ID: 30172722
[TBL] [Abstract][Full Text] [Related]
22. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
23. Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up.
Finn RS; Rugo HS; Gelmon KA; Cristofanilli M; Colleoni M; Loi S; Schnell P; Lu DR; Theall KP; Mori A; Gauthier E; Bananis E; Turner NC; Diéras V
Oncologist; 2021 May; 26(5):e749-e755. PubMed ID: 33486783
[TBL] [Abstract][Full Text] [Related]
24. Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.
Masuda N; Mukai H; Inoue K; Rai Y; Ohno S; Mori Y; Hashigaki S; Muramatsu Y; Umeyama Y; Iwata H; Toi M
Breast Cancer; 2019 Sep; 26(5):637-650. PubMed ID: 31127500
[TBL] [Abstract][Full Text] [Related]
25. HER2-low expression does not affect the clinical outcomes of metastatic breast cancer treated with CDK4/6 inhibitor: A real-world study.
Shao Y; Luo Z; Yu Y; Chen Q; He Y; Liu C; Nie B; Zhu F; Liu H
Front Endocrinol (Lausanne); 2022; 13():1000704. PubMed ID: 36060981
[TBL] [Abstract][Full Text] [Related]
26. Systematic review and meta-analysis of post-progression outcomes in ER+/HER2- metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials.
Munzone E; Pagan E; Bagnardi V; Montagna E; Cancello G; Dellapasqua S; Iorfida M; Mazza M; Colleoni M
ESMO Open; 2021 Dec; 6(6):100332. PubMed ID: 34864350
[TBL] [Abstract][Full Text] [Related]
27. Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer.
Finn RS; Liu Y; Zhu Z; Martin M; Rugo HS; Diéras V; Im SA; Gelmon KA; Harbeck N; Lu DR; Gauthier E; Huang Bartlett C; Slamon DJ
Clin Cancer Res; 2020 Jan; 26(1):110-121. PubMed ID: 31527167
[TBL] [Abstract][Full Text] [Related]
28. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.
Rugo HS; Finn RS; Diéras V; Ettl J; Lipatov O; Joy AA; Harbeck N; Castrellon A; Iyer S; Lu DR; Mori A; Gauthier ER; Bartlett CH; Gelmon KA; Slamon DJ
Breast Cancer Res Treat; 2019 Apr; 174(3):719-729. PubMed ID: 30632023
[TBL] [Abstract][Full Text] [Related]
29. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
[TBL] [Abstract][Full Text] [Related]
30. Palbociclib and Letrozole in Advanced Breast Cancer.
Finn RS; Martin M; Rugo HS; Jones S; Im SA; Gelmon K; Harbeck N; Lipatov ON; Walshe JM; Moulder S; Gauthier E; Lu DR; Randolph S; Diéras V; Slamon DJ
N Engl J Med; 2016 Nov; 375(20):1925-1936. PubMed ID: 27959613
[TBL] [Abstract][Full Text] [Related]
31. Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.
Diéras V; Harbeck N; Joy AA; Gelmon K; Ettl J; Verma S; Lu DR; Gauthier E; Schnell P; Mori A; Rugo HS; Finn RS
Oncologist; 2019 Dec; 24(12):1514-1525. PubMed ID: 31217344
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2.
Cameron D; Kumar Sharma V; Biswas C; Clarke C; Chandiwana D; Pathak P
J Med Econ; 2023; 26(1):357-365. PubMed ID: 36797664
[TBL] [Abstract][Full Text] [Related]
33. Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.
Ettl J; Im SA; Ro J; Masuda N; Colleoni M; Schnell P; Bananis E; Lu DR; Cristofanilli M; Rugo HS; Finn RS
Breast Cancer Res; 2020 Mar; 22(1):27. PubMed ID: 32164785
[TBL] [Abstract][Full Text] [Related]
34. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
35. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
[TBL] [Abstract][Full Text] [Related]
36. Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment.
Bell T; Crown JP; Lang I; Bhattacharyya H; Zanotti G; Randolph S; Kim S; Huang X; Huang Bartlett C; Finn RS; Slamon D
Curr Med Res Opin; 2016 May; 32(5):959-65. PubMed ID: 26894413
[TBL] [Abstract][Full Text] [Related]
37. Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Rugo HS; Turner NC; Finn RS; Joy AA; Verma S; Harbeck N; Masuda N; Im SA; Huang X; Kim S; Sun W; Iyer S; Schnell P; Bartlett CH; Johnston S
Eur J Cancer; 2018 Sep; 101():123-133. PubMed ID: 30053671
[TBL] [Abstract][Full Text] [Related]
38. Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA.
Masurkar PP; Damgacioglu H; Deshmukh AA; Trivedi MV
Pharmacoeconomics; 2023 Jun; 41(6):709-718. PubMed ID: 36920662
[TBL] [Abstract][Full Text] [Related]
39. Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials.
Finn RS; Cristofanilli M; Ettl J; Gelmon KA; Colleoni M; Giorgetti C; Gauthier E; Liu Y; Lu DR; Zhang Z; Bartlett CH; Slamon DJ; Turner NC; Rugo HS
Breast Cancer Res Treat; 2020 Nov; 184(1):23-35. PubMed ID: 32783178
[TBL] [Abstract][Full Text] [Related]
40. Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2- Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate.
Fein L; Lazaretti N; Chuken YL; Benfield JRGR; Mano MS; Lobaton J; Korbenfeld E; Damian F; Lu DR; Mori A; Patyna SJ; Franco S
Clin Drug Investig; 2023 Sep; 43(9):699-706. PubMed ID: 37594640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]